

## TAKE THE FIRST CHANCE NOW In the 1<sup>st</sup> line treatment of DLBCL

R-CHOP has been the standard of care for 1L DLBCL but its treatment outcomes left much to be desired with cure rates of only 60% and relapse/refractory rate of up to 40%<sup>1-3</sup>

Despite the addition of various strategies of : <sup>4-14</sup>



Most have failed to show an efficacy benefit with suboptimal HR values and statistically insignificant results.<sup>4-14</sup>

#### Double-blind, randomized controlled trial<sup>15</sup> POLARIX Collaboration with LYSA • NCT03274492 Arm A (n=440) Cycles 7 and 8 POLIVY<sup>®</sup> 1.8mg/kg Rituximab R-CHP + vincristine placebo Patients (n=879) 375mg/m<sup>2</sup> Q21D x6 cycles R 1:1 Previously untreated DLBCL Age 18-80 years IPI score 2-5 Arm B (n=439) Cycles 7 and 8 ECOG PS 0-2 R-CHOP + POLIVY<sup>®</sup> placebo Rituximab Q21D x6 cycles 375mg/m<sup>2</sup> PFS assessed by investigator **Primary endpoint** Stratification factors IPI score (2 vs. 3-5) Bulky disease Key secondary EFS assessed by investigator, PET-CT CR at end of trial assessed by BICR, OS and safety $(\geq 7.5 \text{ cm vs. absence})$ endpoints Geographic region

Indication: POLIVY® in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated DLBCL<sup>®</sup>

Abbreviations: IL: First line; BICR: Blinded Independent Central Review; CD20: Cluster of differentiate 20; CR: Complete response; CT: Computerized tomography; DLBCL: Diffuse large B-cell lymphoma; EC0G PS: Eastern Cooperative Oncology Group performance status; EFS: Event-free survival; LYSA: Lymphoma Study Association; OS: Overall survival; PET: Positron emission tomography; PFS: Progression-free survival; Pola-R-CHP: Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisone; 021D: Every 21 days; R-CHOP: Rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisone

## How does POLIVY<sup>®</sup> work?

#### The novel antibody-drug conjugate

The mAb part of POLIVY<sup>®</sup> binds with high affinity and selectivity to CD79b, a cell surface component of the B-cell receptor. After binding to CD79b on the B-cell surface, POLIVY<sup>®</sup> is internalized, and the linker is cleaved. MMAE is released into the cell, result in inhibiting division and inducing apoptosis.<sup>16-19</sup>



### **Prolong the PFS in 1L DLBCL patients**

Reduce the risk of progression, relapse, or death by 27% with Pola-R-CHP

#### Investigator-assessed PFS (global ITT population) in the POLARIX Trial<sup>15</sup>



Abbreviations: CD79b: Cluster of differentiate 79b; CI: Confidence interval; HR: Hazard ratio; ITT: Intention to treat; mAB: Monoclonal antibody; MMAE: Monomethyl auristatin E; PFS: Progression-free survival; Pola-R-CHP: Polatuzumab vedotir rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisone

## PFS benefits in the Asia subpopulation analysis

Consistent with the ITT group with Pola-R-CHP vs. R-CHOP



## No additional safety concerns

As compared with R-CHOP<sup>15</sup>

AE, n (%)		Pola-R-CHP (n=435)	R-CHOP (n=438)	
Any-grade AEs			426 (97.9)	431 (98.4)
Grade 3-4 AEs			251 (57.7)	252 (57.5)
SAEs			148 (34.0)	134 (30.6)
Grade 5 AEs			13 (3.0)	10 (2.3)
AEs leading to treatment discontinuation				
Any treatment			27 (6.2)	29 (6.6)
POLIVY <sup>®</sup> / incristine			19 (4.4)	22 (5.0)
AEs leading to dose reduction of any treatment			40 (9.2)	57 (13.0)
No additional rates of discontinuations with Pola-R-CHP as compared with R-CHOP <sup>15, 21</sup>				
Completed 6 cycles of treatment Comp		pleted all 8 cycles of treatment		
Pola-R-CHP	R-CHOP	Pola-	R-CHP	R-CHOP
91.7%	88.5%	89	.2%	86.3%

Abbreviations: AEs: Adverse events; CI: Confidence interval; HR: Hazard ratio; ITT: Intention to treat; PFS: Progression-free survival; Pola-R-CHP: Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisone; R-CHOP: Rituximab, cyclophosphamide, doxorubicin hydrochloride, interval; HR: Hazard ratio; ITT: Intention to treat; PFS: Progression-free survival; Pola-R-CHP: Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisone; SAEs: Serious adverse events

#### Investigator-assessed PFS of the Asia subpopulation analysis20



#### Scan the QR Code for more information on POLARIX trial

Abbreviations: 11: First line; DLBCL: Diffuse large B-cell lymphoma; OS: Overall survival; PFS: Progression-free survival; Pola-R-CHP: Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisone; R-CHOP: Rituximab, cyclophosphamide, doxOrubicin hydrochloride, vincristine sulfate, and prednisone

References: 1. Sarkozy C, Sehn LH. Best Pract Res Clin Haematol. 2018;31(3):209-216. 2. Maurer MJ, Ghesquières H, Jais JP, et al. J Clin Oncol. 2014;32(10):1066-1073. 3. Sehn LH, Salles G. N Engl J Med. 2021;384(9):842-858. 4. Vitolo U, Trněný M, Belada D, et al. J Clin Oncol. 2017;35(3):3529-3537. 5. Vitolo U, et al. Hematol Oncol. 2019;37:36-37. 6. Davies A, et al. Lancet Oncol. 2019:20:649-62. 7. Younes A, et al. J Clin Oncol. 2019;37:1285-95. 8. Seymour JF, et al. J Clin Oncol. 2019;31:497-49. 9. Aurer I, et al. Eur J Haematol. 2018;31:1457-45. 12. Crump M, et al. J Clin Oncol. 2019;37:1285-95. 8. Seymour JF, et al. J Din Oncol. 2019;37:1790-99. 11. Cunningham D, et al. Lancet. 2013;381:1817-26. 12. Crump M, et al. J Clin Oncol. 2016;34:2484-92. 13. Witzig TE, et al. Ann Oncol. 2018;29:707-14. 14. Jaeger U, et al. Haematologica. 2015;100:955-63. 15. Tilly H, et al. New Engl J Med. 2022;386:351-63. 16. POLIVY® Prescribing information. Roche Singapore Pte Ltd. January 2023. 17. Polson A, et al. Expert Opin Invest Drug. 2011;20:75-85. 18. Doronina SO, et al. Nat Biotechnol. 2003;21:778-84. 19. Dornan D, et al. Blood. 2009;14:2721-29. 20. Song Y, et al. J Clin Oncol. Jun 2022;40(16\_suppl):7558-7558. 21. European Medicines Agency. March 24, 2022. Publication No. EMA/CHMP/PRAC/112106/2022.



# Before prescribing POLIVY®, please consult the full local information by scanning the QR code or visit https://www.roche.com.sg/en/pharma/polivy.html

SAFETY REPORTING FOR POTENTIAL UNDESIRABLE EFFECTS: Please report any adverse events to the local Roche Adverse Event email at singapore.drugsafety@roche.com or call (65) 6735 0550. This will enable Roche to better understand the safety of POLIVY® and to provide appropriate information to Health Authorities, Heathcare Providers and patients.



For Healthcare Professionals Only, Roche Singapore Pte Ltd, 1 Paya Lebar Link, #09-03 PLQ 1, Paya Lebar Quarter, Singapore 408533. M-SG-00001015-Mar-2023